PATRICK  FORDE

PATRICK FORDE

Hematology & Oncology



Professional Links



KOL Overview:

Dr. Patrick Forde is an adjunct professor of Oncology at Johns Hopkins Medicine.  He is also the Co-director of the Division of Upper Aerodigestive Malignancies and the Director of the Thoracic Oncology Clinical Research Program. As an accomplished researcher, his presentations from the stage are often celebrated by his peers, and he is a very active contributor to the lung cancer social media community, His tweets are among the most engaging among his peers to include discussions on major clinical trials such as LAURA, CHECKMATE 816, CHECKMATE 73L, KEYNOTE-671, and PACIFIC-2. As the lead author of CHECKMATE 816, Dr. Forde 's presentations were highlighted by his peers and he also took the opportunity to support his fellow investigators.

Advocating Evidence-Based Approaches

Dr. Forde shares both good and bad news regarding clinical trial outcomes. Below is an example of the update on CHECKMATE 73L, and his commentary on the impact on patient care:

Dr. Forde was one of the first key opinion leaders to celebrate the success of the LAURA trial and declare a new standard of care:

Engaging in Constructive Discussions

Dr. Forde’s social media presence is marked by his active participation in constructive discussions. Whether it’s analyzing the implications of the LAURA trial or debating the merits of crossover in clinical trials, he engages his peers with thought-provoking questions and evidence-based arguments

His interactions indicate a persona committed to intellectual rigor and collaborative advancement.

Social Media Style

Dr. Patrick Forde is a modern key opinion leader, respected for his research and presentations from the stage, and also a key member of the social discussions on clinical trials that impact patient care across modalities of lung cancer treatment.  He engages with the tweets of his peers and shares data to spur discussions and debate.  His tweets and research carry significant weight with his colleagues and he recognizes the arguments of physicians across the spectrum of a debate.



Total Payments 2017-2023 to Dr.PATRICK FORDE: $191,520

Company Total 2017 2018 2019 2020 2021 2022 2023

E.R. Squibb & Sons, L.L.C.

$43,109

$8,105

$137

$0

$0

$5,850

$22,129

$6,889

Regeneron Pharmaceuticals, Inc.

$24,997

$0

$0

$0

$0

$0

$3,101

$21,896

AstraZeneca UK Limited

$23,580

$0

$7,947

$0

$1,250

$4,110

$4,795

$5,478

AstraZeneca Pharmaceuticals LP

$22,038

$506

$389

$1,385

$0

$3,425

$11,777

$4,557

GENZYME CORPORATION

$16,949

$0

$0

$0

$0

$2,616

$14,333

$0



Top Tweets

KOL PulseRank

Clinical Trial Tweets Peer Outreach Peer Engagement
CHECKMATE 816 1 12 18
CHECKMATE 73L 1 7 16
KEYNOTE-671 3 9 15
PACIFIC-2 2 15 14